Utility of PSA isoform-[-2]proPSA (p2PSA) and prostate health index in the diagnosis of prostate cancer: A study in Indian population

被引:0
|
作者
Govinda, Raju N. L. [1 ,3 ]
Bhat, Parineetha [2 ]
Nagini, S. [3 ]
机构
[1] Apollo Hosp, Dept Clin Biochem, Bangalore 560076, Karnataka, India
[2] St Peters Med Coll, Dept Biochem, Hosur 635130, Tamil Nadu, India
[3] Annamalai Univ, Dept Biochem & Biotechnol, Annamalainagar 608002, Tamil Nadu, India
关键词
Prostate Cancer; P2PSA; Prostate Health Index; ANTIGEN PSA; 2-10; NG/ML; MEN; PHI; BIOPSY; RANGE; LEVEL; RISK;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Measurement of serum total Prostate Specific Antigen (tPSA) for diagnosis of Prostate Cancer (PC) has some limitations since PSA is organ-specific and not disease-specific. Studies across the globe have shown that measuring the isoform of PSA: [-2]-Pro-PSA(p2PSA) and calculating the Prostate Health Index (PHI) increase the specificity, however, very few studies have been done in the Indian population. Aim and Objectives: To evaluate tPSA, p2PSA and PHI as diagnostic markers of PC. Material and Methods: The pre-biopsy blood samples of 152 subjects were analysed in Beckman-Coulter Access-2 for tPSA, freePSA (fPSA) and p2PSA and %fPSA, %p2PSA and PHI ([p2PSA/fPSA] x root tPSA) were calculated. Validity indicators were calculated along with Area under the receiver operating Curve (AUC). Results: Of 152 subjects, 85 subjects (55.9 %) had PC, and others showed No evidence of Malignancy (NEM). The median tPSA (ng/ml), p2PSA (pg/ml), %p2PSA,IPSA (pg/ml) and PHI values were significantly (p<0.001) higher in the PC group than NEM group (148 ng/ml vs. 9.11 ng/ml; 612.3 pg/ml vs. 14.52 pg/ml; 4.98% vs. 1.59 %; 15.7 pg/ml vs. 1.26 pg/ml and 440.19 vs. 32.14 respectively). PSA at cut off value of 10 ng/ml had 91.8% sensitivity, 58.2% specificity, Negative Predictive Value (NPV) 84.8% and Positive Predictive Value (PPV) 73.6%. At a cut-off of 100 pg/ml p2PSA had 81.7% sensitivity, 97.0% specificity, 80.2% NPV, 97.2 % PPV and AUC was 0.930 [95% Confidence Interval(CI): 0.88-0.97]. PHI had 91.8% sensitivity, 55.2% specificity, 84.1% NPV, 72.2% PPV and AUC was 0.919 (95% CI 0.86-0.96). Conclusion: Using multiple biomarkers like P2PSA and PHI with better specificity can aid in the diagnosis of PC.
引用
收藏
页码:45 / 54
页数:10
相关论文
共 50 条
  • [1] Clinical Use of [-2] proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
    Abrate, Alberto
    Lughezzani, Giovanni
    Gadda, Giulio Maria
    Lista, Giuliana
    Kinzikeeva, Ella
    Fossati, Nicola
    Larcher, Alessandro
    Dell'Oglio, Paolo
    Mistretta, Francesco
    Buffi, Nicolomaria
    Guazzoni, Giorgio
    Lazzeri, Massimo
    KOREAN JOURNAL OF UROLOGY, 2014, 55 (07) : 436 - 445
  • [2] Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer
    Filella, Xavier
    Foj, Laura
    Maria Auge, Josep
    Molina, Rafael
    Alcover, Joan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (09) : 1347 - 1355
  • [3] Age-specific reference intervals for Prostate-Specific-Antigen (PSA), its isoform-[-2] pro-PSA (p2PSA) and prostate health index in Indian males
    Raju, N. L. Govinda
    Kumar, V. Vinoth
    Supriya
    Bhat, Parineetha P.
    JOURNAL OF KRISHNA INSTITUTE OF MEDICAL SCIENCES UNIVERSITY, 2024, 13 (02) : 78 - 89
  • [4] Establishment of reference intervals for serum [-2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
    Wu, Zhi-Yu
    Yang, Cheng
    Luo, Jie
    Deng, Shao-Li
    Wu, Bin
    Chen, Ming
    ONCOTARGETS AND THERAPY, 2019, 12 : 6453 - 6460
  • [5] PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer
    Ayyildiz, Sema Nur
    Ayyildiz, Ali
    TURKISH JOURNAL OF UROLOGY, 2014, 40 (02): : 82 - 88
  • [6] Clinical cut-offs of isoform [-2]proPSA (p2PSA) derivatives, namely %p2PSA and PHI (Prostate Health Index) for guiding biopsy decision in Caucasian population
    Lughezzani, G.
    Lazzeri, M.
    Scattoni, V
    Larcher, A.
    Gadda, G.
    Nava, L.
    Lista, G.
    Bini, V
    Freschi, M.
    Rigatti, L.
    Rigatti, P.
    Guazzoni, G.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E909 - U911
  • [7] SERUM ISOFORM [-2]PROPSA (P2PSA) AND ITS DERIVATES, %P2PSA AND PHI (PROSTATE HEALTH INDEX), ARE MORE ACCURATE OF REFERENCE STANDARD TEST (PSA) IN MEN SCHEDULED FOR REPEAT BIOPSY
    Lazzeri, Massimo
    Lughezzani, Giovanni
    Scattoni, Vincenzo
    Bini, Vittorio
    Larcher, Alessandro
    Cestari, Andrea
    Gadda, Giulio Maria
    Maga, Tommaso
    Rigatti, Patrizio
    Montorsi, Francesco
    Guazzoni, Giorgio
    JOURNAL OF UROLOGY, 2012, 187 (04): : E898 - E898
  • [8] DIAGNOSTIC ACCURACY OF [-2]PROPSA (P2PSA) AND ITS DERIVATIVES %P2PSA AND PHI (PROSTATE HEALTH INDEX) IN A REAL CLINICAL SETTING OF CONTEMPORARY MEN UNDERGOING PROSTATE BIOPSY FOR SUSPECTED PROSTATE CANCER
    Nava, L.
    Lazzeri, M.
    Lughezzani, G.
    Losa, A.
    Maga, T.
    Fabbri, F.
    Cestari, A.
    Maccagnano, C.
    Scattoni, V
    Bini, V
    Buffi, N.
    Guazzoni, G.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 206 - 206
  • [9] SERUM ISOFORM [-2]PROPSA (P2PSA) AND ITS DERIVATES, %P2PSA AND PHI (PROSTATE HEALTH INDEX), ARE MORE ACCURATE THAN THE REFERENCE STANDARD TEST (PSA) IN MEN SCHEDULED FOR REPEAT BIOPSY
    Larcher, Alessandro
    Lazzeri, Massimo
    Lughezzani, Giovanni
    Gadda, Giulio
    Abrate, Alberto
    Scattoni, Vincenzo
    Sangalli, Mattia
    Nava, Luciano
    Bin, Vittorio
    Maga, Tommaso
    Bellinzoni, Piera
    Cestari, Andrea
    Rigatti, Patrizio
    Guazzoni, Giorgio
    ANTICANCER RESEARCH, 2012, 32 (05) : 1850 - 1851
  • [10] Serum isoform [-2]proPSA (p2PSA) and its derivates, %p2PSA and PHI (prostate health index), are more accurate than the reference standard test (PSA) in men scheduled for repeat biopsy
    Lazzeri, M.
    Lughezzani, G.
    Larcher, A.
    Gadda, G.
    Scattoni, V
    Sangalli, M.
    Nava, L.
    Bini, V
    Maga, T.
    Bellinzoni, P.
    Cestari, A.
    Rigatti, P.
    Guazzoni, G.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E259 - E259